RankAlpha logo
Back to Rankings

VOR

Vor BiopharmaB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
The investment case rests on telitacicept as the company's focused asset, two global Phase 3 programs, prior China regulatory validation, and substantial liquidity. The prior company release projected funding into early 2029, but that runway has not been freshly reaffirmed in the post-print evidence.
Posture
Constructive
Lead driver
Sentiment
What changed
4 setup hits (3d) with net bullish as of 2026-09-09.
What can break
No reliable post-earnings consensus surprise, analyst revision, transcript, or event-attributed price reaction was available in the reviewed evidence.
Momentum
87
Value
41
Sentiment
76
Setup hits (3d)
4 · Net Bullish
AI TargetsBase $25.00 · Bull $40.00 · Bear $12.00Analysis 2026-08-13; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-13 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-09-09

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions

Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bullish
Target $39.00
Why
Momentum87 · Δ7d -1.0
Value41 · Δ7d 0.0
Sentiment76 · Δ7d -7.0
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.

Confirming evidence

  • • 4 setup hits (3d) with net bullish as of 2026-09-09.
  • • Sentiment remains the lead driver in the composite, 7D delta -7.0.

Contradictions & invalidation

  • • No reliable post-earnings consensus surprise, analyst revision, transcript, or event-attributed price reaction was available in the reviewed evidence.
  • • Phase 3 efficacy, safety, enrollment, or regulatory setbacks could materially impair value.
  • • The thesis remains binary and execution-dependent: Phase 3 enrollment and outcomes must support approval, the company has no commercial operating history, losses continue, and warrant liabilities create substantial balance-sheet and valuation noise.

Catalyst clock

2026-08-11

Q2 2026 filing confirms liquidity but highlights warrant and loss volatility

Lead driver: Sentiment · See AI snapshot
Momentum
87
9% active weight
Current posture
7d trendFlat
Δ7d
-1.0
Δ21d
-9.2
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
76
62% active weight
Current posture
7d trendSoftening
Δ7d
-7.0
Δ21d
-8.2
Why this grade

Composite grade B. Momentum 87.3 / Value 41.2 / Sentiment 75.6

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-13. Scenario method

B+
Bull case
25%
Probability
Target price
$40.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
Most likely
B
Base case
50%
Probability
Target price
$25.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$1.36B
Beta
2.03
Shares Out
59.16M
P/E (TTM) · Derived
-0.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.30
Rev YoY
-
EPS YoY
-99.5%
Gross Margin
-
Op Margin
-
Net Debt
-$452.21M
Current Ratio
19.15
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data